Journal for ImmunoTherapy of Cancer (Nov 2023)
1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors
- Jay S Fine,
- Louis Matis,
- Stella Martomo,
- Xingyue An,
- Mohosin Sarkar,
- Abudukadier Abulizi,
- Guixian Jin,
- Evelyn Teran,
- Danielle Klaskin,
- Maria Hackett,
- Hayden Karp,
- Julio Rodriguez,
- Sonali Dhindwal,
- Changqing Yuan,
- Zengzu Lai,
- Jennifer Zeiger,
- Amber Fearnley,
- Oksana A Sergeeva,
- Eric M Tam,
- Tracy Lichter,
- Jeremy S Myers
Affiliations
- Jay S Fine
- EvolvImmune Therapeutics, Branford, CT, USA
- Louis Matis
- EvolvImmune Therapeutics, Branford, CT, USA
- Stella Martomo
- EvolvImmune Therapeutics, Branford, CT, USA
- Xingyue An
- EvolvImmune Therapeutics, Branford, CT, USA
- Mohosin Sarkar
- EvolvImmune Therapeutics, Branford, CT, USA
- Abudukadier Abulizi
- EvolvImmune Therapeutics, Branford, CT, USA
- Guixian Jin
- EvolvImmune Therapeutics, Branford, CT, USA
- Evelyn Teran
- EvolvImmune Therapeutics, Branford, CT, USA
- Danielle Klaskin
- EvolvImmune Therapeutics, Branford, CT, USA
- Maria Hackett
- EvolvImmune Therapeutics, Branford, CT, USA
- Hayden Karp
- EvolvImmune Therapeutics, Branford, CT, USA
- Julio Rodriguez
- EvolvImmune Therapeutics, Branford, CT, USA
- Sonali Dhindwal
- EvolvImmune Therapeutics, Branford, CT, USA
- Changqing Yuan
- EvolvImmune Therapeutics, Branford, CT, USA
- Zengzu Lai
- EvolvImmune Therapeutics, Branford, CT, USA
- Jennifer Zeiger
- EvolvImmune Therapeutics, Branford, CT, USA
- Amber Fearnley
- EvolvImmune Therapeutics, Branford, CT, USA
- Oksana A Sergeeva
- EvolvImmune Therapeutics, Branford, CT, USA
- Eric M Tam
- EvolvImmune Therapeutics, Branford, CT, USA
- Tracy Lichter
- EvolvImmune Therapeutics, Branford, CT, USA
- Jeremy S Myers
- EvolvImmune Therapeutics, Branford, CT, USA
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.1392
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
